0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Anticancer Agent"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
Research Report on China's Lobaplatin Market, 2021-2025 - Product Thumbnail Image

Research Report on China's Lobaplatin Market, 2021-2025

  • Report
  • September 2021
  • 40 Pages
  • China
From
EUR$2,600USDGBP
From
EUR$2,600USDGBP
FTase (Farnesyltransferase) inhibitor- Pipeline Insight, 2024 - Product Thumbnail Image

FTase (Farnesyltransferase) inhibitor- Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
EUR$1,500USDGBP
Checkpoint Inhibitors - Competitive landscape, 2023 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive landscape, 2023

  • Report
  • April 2023
  • 350 Pages
  • Global
From
EUR$3,250USDGBP
Antibody Drug Conjugates Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Antibody Drug Conjugates Market - Forecasts from 2024 to 2029

  • Report
  • February 2024
  • 210 Pages
  • Global
From
EUR$4,250USDGBP
From
EUR$3,750USDGBP
From
EUR$3,750USDGBP
Proto-oncogene protein c mdm2 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Proto-oncogene protein c mdm2 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
EUR$1,500USDGBP
Histone deacetylase (HDAC) Inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Histone deacetylase (HDAC) Inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 150 Pages
  • Global
From
EUR$2,500USDGBP
Proto oncogene proteins c pim 1 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Proto oncogene proteins c pim 1 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
EUR$1,500USDGBP
CD3 antigen inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

CD3 antigen inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
EUR$1,500USDGBP
From
EUR$7,500USDGBP
From
EUR$3,950USDGBP
CTLA-4 inhibitors- Competitive landscape, 2023 - Product Thumbnail Image

CTLA-4 inhibitors- Competitive landscape, 2023

  • Report
  • May 2023
  • 220 Pages
  • Global
From
EUR$2,500USDGBP
From
EUR$7,500USDGBP
Chemotherapy Induced Diarrhea - Epidemiology Forecast - 2032 - Product Thumbnail Image

Chemotherapy Induced Diarrhea - Epidemiology Forecast - 2032

  • Report
  • February 2023
  • 60 Pages
  • Global
From
EUR$3,950USDGBP
Loading Indicator

The Anticancer Agent market is a segment of the Healthcare Services industry that focuses on the development and distribution of drugs and treatments for cancer. These agents are designed to target and destroy cancer cells while minimizing the damage to healthy cells. They can be administered orally, intravenously, or topically, depending on the type of cancer and the patient's individual needs. Anticancer agents are used in combination with other treatments such as radiation and chemotherapy to provide the best possible outcome for the patient. The Anticancer Agent market is highly competitive, with many companies vying for market share. Companies in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more